Nonmyeloablative HSCT in children and adults from matched related donors
| Reference . | Transplant regimen . | Number of patients (age range, y) . | Alive without SCD . | Acute GVHD . | Chronic GVHD . | Death . | Comments . |
|---|---|---|---|---|---|---|---|
| Hsieh et al, 200948 | TBI 300 cGy, alemtuzumab 1 mg/kg, sirolimus | 10 (16-45 y) | 9 | 0 | 0 | 0 | At 3 y after HSCT, mixed chimerism in all |
| Krishnamurti et al, 200850 | BU 6.4 mg/kg IV or 8 mg/kg PO, FLU 175 mg/kg, ATG, 500 cGy of TLI, CSA, MMF | 7 (6-16) | 6 | 1 (Gr 2 skin) | 1 (limited skin) | 0 | Mixed chimerism in 4 |
| Horwitz et al, 200751 | TBI 200 cGy, FLU 24 mg/m2, Cy 500 mg/m2, alemtuzumab 100 mg, MMF | 2 (21 and 27) | 2 | 0 | 0 | N/A | Mixed chimerism in both |
| Horan et al, 200545 | TBI 200 cGy, FLU 125 mg/m2, ATG, CSA, MMF | 3 (9-30) | 1 | 0 | 0 | 0 | |
| Shenoy, 200557 | Melphalan 140 mg/m2, FLU 150 mg/m2, alemtuzumab 48 mg, CSA + MTX | 1 (2) | N/A | 0 | 0 | N/A | |
| Jacobsohn et al, 200429 | BU 6.4 mg/kg IV, FLU 180 mg/m2, ATG, CSA, MMF | 1 (22) | 0 | 1 (Gr 1) | 1 (extensive) | 1 (GVHD) | |
| Iannone et al, 200334 | TBI 200 cGy, FLU 150 mg/m2, CSA or tacrolimus, MMF | 6 (3-20) | 0 | 1 (Gr 2) | 0 | 0 | Transient engraftment in 5 patients for 97-441 days |
| van Besien et al, 200058 | Melphalan 140 mg/m2, FLU 120 mg/m2, ATG, tacrolimus, MTX | 2 (40 and 56) | 0 | 1 (Gr 2 skin) 1 (gut and Gr 3 liver) | 1 (severe lung) | 2 (lung GVHD, liver GVHD and CNS infection) |
| Reference . | Transplant regimen . | Number of patients (age range, y) . | Alive without SCD . | Acute GVHD . | Chronic GVHD . | Death . | Comments . |
|---|---|---|---|---|---|---|---|
| Hsieh et al, 200948 | TBI 300 cGy, alemtuzumab 1 mg/kg, sirolimus | 10 (16-45 y) | 9 | 0 | 0 | 0 | At 3 y after HSCT, mixed chimerism in all |
| Krishnamurti et al, 200850 | BU 6.4 mg/kg IV or 8 mg/kg PO, FLU 175 mg/kg, ATG, 500 cGy of TLI, CSA, MMF | 7 (6-16) | 6 | 1 (Gr 2 skin) | 1 (limited skin) | 0 | Mixed chimerism in 4 |
| Horwitz et al, 200751 | TBI 200 cGy, FLU 24 mg/m2, Cy 500 mg/m2, alemtuzumab 100 mg, MMF | 2 (21 and 27) | 2 | 0 | 0 | N/A | Mixed chimerism in both |
| Horan et al, 200545 | TBI 200 cGy, FLU 125 mg/m2, ATG, CSA, MMF | 3 (9-30) | 1 | 0 | 0 | 0 | |
| Shenoy, 200557 | Melphalan 140 mg/m2, FLU 150 mg/m2, alemtuzumab 48 mg, CSA + MTX | 1 (2) | N/A | 0 | 0 | N/A | |
| Jacobsohn et al, 200429 | BU 6.4 mg/kg IV, FLU 180 mg/m2, ATG, CSA, MMF | 1 (22) | 0 | 1 (Gr 1) | 1 (extensive) | 1 (GVHD) | |
| Iannone et al, 200334 | TBI 200 cGy, FLU 150 mg/m2, CSA or tacrolimus, MMF | 6 (3-20) | 0 | 1 (Gr 2) | 0 | 0 | Transient engraftment in 5 patients for 97-441 days |
| van Besien et al, 200058 | Melphalan 140 mg/m2, FLU 120 mg/m2, ATG, tacrolimus, MTX | 2 (40 and 56) | 0 | 1 (Gr 2 skin) 1 (gut and Gr 3 liver) | 1 (severe lung) | 2 (lung GVHD, liver GVHD and CNS infection) |
ATG indicates antithymocyte globulin; cGy, centi-Gray; CSA, cyclosporine A; Cy; cyclophosphamide; FLU, fludarabine; Gr, grade; IV, intravenous; MMF, mycophenolate mofetil; MTX, methotrexate; N/A, not applicable; PO, per orally; SCD, sickle cell disease; TBI, total body irradiation; and TLI, total lymphoid irradiation.